A number of other research analysts have also weighed in on the company. ValuEngine lowered Natus Medical from a buy rating to a hold rating in a research note on Tuesday, January 29th. Zacks Investment Research lowered Natus Medical from a hold rating to a strong sell rating in a research note on Friday, February 15th. Finally, TheStreet lowered Natus Medical from a c- rating to a d+ rating in a research note on Thursday, April 25th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $36.00.
Shares of Natus Medical stock opened at $26.37 on Monday. Natus Medical has a fifty-two week low of $23.58 and a fifty-two week high of $37.95. The firm has a market cap of $906.93 million, a price-to-earnings ratio of 18.57 and a beta of 0.54. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.18 and a current ratio of 1.70.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.03. Natus Medical had a positive return on equity of 10.75% and a negative net margin of 8.62%. The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $113.30 million. During the same quarter in the prior year, the company posted $0.24 EPS. The business’s revenue for the quarter was down 10.7% compared to the same quarter last year. Analysts expect that Natus Medical will post 1.27 earnings per share for the current fiscal year.
In related news, VP Austin Francis Noll III sold 14,250 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $26.43, for a total value of $376,627.50. Following the transaction, the vice president now directly owns 99,443 shares of the company’s stock, valued at approximately $2,628,278.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert A. Gunst sold 6,304 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $27.96, for a total value of $176,259.84. Following the completion of the transaction, the director now directly owns 32,392 shares in the company, valued at $905,680.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 52,873 shares of company stock worth $1,420,976. Corporate insiders own 1.65% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of BABY. Vaughan Nelson Investment Management L.P. purchased a new position in shares of Natus Medical in the 4th quarter worth $33,985,000. Norges Bank purchased a new position in shares of Natus Medical in the 4th quarter worth $11,884,000. BlackRock Inc. raised its position in shares of Natus Medical by 3.5% in the 4th quarter. BlackRock Inc. now owns 5,191,158 shares of the medical equipment provider’s stock worth $176,656,000 after buying an additional 177,465 shares during the period. WCM Investment Management LLC raised its position in shares of Natus Medical by 68.8% in the 1st quarter. WCM Investment Management LLC now owns 403,183 shares of the medical equipment provider’s stock worth $10,233,000 after buying an additional 164,313 shares during the period. Finally, Morgan Stanley raised its position in shares of Natus Medical by 168.9% in the 3rd quarter. Morgan Stanley now owns 200,720 shares of the medical equipment provider’s stock worth $7,157,000 after buying an additional 126,079 shares during the period. 86.89% of the stock is currently owned by institutional investors and hedge funds.
Natus Medical Company Profile
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Featured Story: Derivative
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.